Creating a new vaccine to treat prostate cancer
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
['FUNDING_SBIR_2'] · IMMUNOVA THERAPEUTICS, LLC · NIH-10662536
This study is testing a new type of vaccine that could help fight prostate cancer in patients with specific tumors, aiming to boost the body's immune response without needing special cells, and it hopes to improve treatment results based on encouraging early findings in mice.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IMMUNOVA THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (MONROVIA, UNITED STATES) |
| Trial ID | NIH-10662536 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel vaccine technology called self-assembled peptide nanoparticles (SAPNANO) to treat prostate cancer, particularly in patients with NY-ESO-1 positive tumors. The vaccine aims to induce strong immune responses against prostate cancer cells without the need for dendritic cells, which are typically used in other immunotherapy approaches. By delivering the vaccine intravenously, the goal is to enhance the body's ability to fight cancer and potentially eliminate tumor cells. The research is based on promising results from mouse models, indicating that this vaccine could significantly improve treatment outcomes for prostate cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who have tumors expressing the NY-ESO-1 antigen.
Not a fit: Patients with prostate cancer that do not express the NY-ESO-1 antigen may not benefit from this vaccine.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While immunotherapy has shown promise in other cancers, this specific approach using SAPNANO technology is novel and has not been widely tested in prostate cancer.
Where this research is happening
MONROVIA, UNITED STATES
- IMMUNOVA THERAPEUTICS, LLC — MONROVIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, YICHENG — IMMUNOVA THERAPEUTICS, LLC
- Study coordinator: WANG, YICHENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer